A primary cutaneous multi-lobed B-cell lymphoma

Multi-lobed non-Hodgkin's lymphoma (NHL) has recently been recognized as a NHL variant. A patient presented with a scalp nodule which, upon skull X-Ray, was seen to be associated with a bone defect. Immunophenotyping clearly demonstrated that this was a B-cell proliferation. Histologically the B-lymphocytes were closely related to centroblasts. There were no other extra cutaneous localizations. The present report emphasizes the importance of this clinico anatomical entity which shows prominent extra-nodal involvement, large lymphoid cells with multi-lobed nuclei and a good response to chemotherapy. Multi-lobed NHL may be a T-cell lymphoma, or a B-cell lymphoma closely related to centroblastic NHL. Although multi-lobed lymphomas have a predilection for cutaneous localizations, our case is the first primary cutaneous multi-lobed B-NHL, proven by immunophenotyping.     

A cutaneous B-cell lymphoma of novel immunophenotype

A case of low-grade B-cell malignant lymphoma with a prolonged restriction to the skin is described. A rearrangement of the immunoglobulin heavy-chain gene was detected using molecular techniques. The histology showed many similarities to primary mucosal lymphomas and this may represent a skin counterpart of these tumours.     

足部皮肤T细胞淋巴瘤1例

报告1例足部皮肤T细胞淋巴瘤。患者男,63岁。左足跟部肿胀4个月,抗感染治疗无效,皮肤组织病理和免疫组化均符合T细胞淋巴瘤。     

原发性皮肤中心母细胞淋巴瘤1例

报告１例原发性皮肤中心母细胞淋巴瘤。患者,男,９２岁。右小腿被蚊虫叮咬后出现肿块１年半,增多、扩大、破溃伴左小中块２个月。血常规、Ｘ光胸片、腹部Ｂ超、骨髓检查未划常。病检示肿瘤细胞形态似中心母细胞,免疫组化证实瘤细胞的Ｂ细胞性。ＥＢＥＲ原位杂交末检测到ＥＢ病毒。患者未作放化疗,９个月后死亡。     

皮肤血管内T细胞淋巴瘤一例

患者女,64岁,6个月前全身出现多发淡红色斑丘疹,质硬,直径1～3 cm,以左侧颜面部及双下肢明显.曾就诊于某医院,诊断为血管炎.1个月前出现头痛、头晕伴步态不稳,同时伴双手及左足麻木、视物模糊,行头颅CT检查提示"右侧额辐射区腔隙性脑梗塞",1个月来步态不稳逐渐加重,再次就诊于当地医院,行头颅MRI检查提示"双侧丘脑、右侧基底节、右侧额叶及右侧小脑半球梗塞,左侧蝶窦旁异常信号灶".患者为进一步诊治于2010年1月至本院治疗,门诊拟诊脑梗死收住入院.皮疹予复方倍他米松注射液、冰黄肤乐软膏等治疗后稍见好转.     

A review of rituximab in cutaneous medicine

The rituximab antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. Rituximab is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma. Rituximab is also commonly used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and immune or idiopathic thrombocytopenic purpura (ITP). Rituximab is an effective treatment for primary cutaneous B-cell lymphoma and other cutaneous lymphomas. Rituximab is an effective treatment for mixed cryoglobulinemia. Rituximab is a promising treatment for systemic lupus erythematosus, dermatomyositis, pemphigus, vasculitis, and a variety of hematologic diseases. Black-box warnings on rituximab include fatal infusion reactions, tumor lysis syndrome, and severe mucocutaneous reactions. A variety of cardiac, pulmonary, renal, and hematologic side effects can occur. It commonly causes mild cutaneous side effect and rarely has caused paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis.     

A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature

INTRODUCTION: Cutaneous T-cell lymphoma subtypes are now better identified thanks to progress in immunohistochemistry. This article describes a new case of primary cutaneous natural killer/T-cell lymphoma of nasal type (NKTL-NT) and reviews 18 other cases of this rare neoplasm. CASE REPORT: A 79-year-old man presented with a 3-cm nodular tumor of the left leg occurring on a primary chronic lymphedema of the legs. The lesion was CD56+, CD3 intracytoplasmic+, CD45+ and Epstein-Barr virus+. A comprehensive workup including CT scan and bone marrow biopsy was negative and a diagnosis of NKTL-NT with a primary cutaneous involvement was made. The patient was free of disease under multi-agent chemotherapy after 24 months of follow-up. DISCUSSION: After reviewing 18 other cases of primary cutaneous NKTL-NT, we conclude that the prognosis of these lymphomas is usually poor. However, limited cutaneous forms have a longer median survival than extracutaneous variants.